Working with leading research institutions, Amsbio has established itself as a premier supplier of high quality Heparan Sulfate (HS) monoclonal antibodies driving breakthroughs in Glycobiology research.
Heparan Sulfate (HS) is widely distributed on cell surfaces and basement membranes in mammals. It participates in important biological processes due to displaying specific interactions with many biologically active proteins. However, due to its non-immunogenic nature, developing effective antibodies against HS has long been a challenge.
Amsbio has overcome these…
Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
One Nucleus, the Cambridge based not-for-profit membership organisation for life science businesses, is delighted to announce the appointment of Melanie Leveridge, Vice President, Assays, Profiling & Cell Sciences, AstraZeneca, as a Non-Executive Director.
Melanie is an established preclinical drug discovery leader with a track record of developing and inspiring diverse, high performing teams, to deliver innovative science and technology. Melanie…
Cambridge, UK, 10 April 2025: Source BioScience UK Ltd, an industry-leading provider of genomic services and histopathology diagnostics, today announced it had completed the acquisition of Cambridge Clinical Laboratories (CCL), a leading Cambridge-based provider of clinical, personalised healthcare testing services. The acquisition bolsters the Company’s clinical diagnostics portfolio by leveraging the expertise of the CCL team and new state-of-the-art clinical lab facilities at Vision Park in Cambridge, providing streamlined testing services for both preclinical and clinical research.
CCL…
London, April 10, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for iOnctura and is pleased to announce the placement of Dr. Mark Velleca as Chair of the Board of Directors.iOnctura is a clinical-stage precision oncology company combating neglected and hard-to-treat cancers with a pipeline of first-in-class small molecules.Dr. Mark Velleca is currently the CEO and Board Chair of Black Diamond Therapeutics (BDTX) and also serves as Board Chair of Myeloid…
Howard Group strengthens its South Cambridge science and healthcare ecosystem with latest signing
Cambridge, 8thApril 2025: Leading regional property investor and developer Howard Group, is pleased to welcome Granta Medical Practices (GMP) to Langford Arch, having agreed a five-year lease for 5,767 sq ft of office space with the primary care provider.
GMP is the latest healthcare business to join Langford Arch, which is adjacent to Howard Group’s flagship science and technology hub, Unity Campus.
GMP is a Primary Care Network providing NHS primary care services to 57,000…
Cancer Research Horizons, the innovation arm of Cancer Research UK, has announced a collaboration with Histofy, a leader in AI-driven histopathology solutions, to develop tools that predict how colorectal cancer patients respond to different treatment options using the multi-modal S:CORT dataset.
As part of the collaboration, Histofy will use digital pathology images, as well as clinical and molecular data, from the S:CORT dataset to further develop and validate AI models that stratify patients into sub-groups based on their likelihood of progressive disease and response to therapy.
The…
The buzzing Cambridge Wide Open annual event returns in June, this time as a week-long interactive festival showcasing Cambridge’s pioneers, the companies of the future, and opening the offices and workspaces that make up one of the world’s most vibrant ecosystems.
Building on the momentum of the last two Cambridge Wide Open Days, the event will run from 9 - 13th June 2025, offering an immersive experience to global investors, ecosystem CEO’s and employees, sci-tech enthusiasts, policymakers, academics, and curious residents alike.
The city’s leading companies and science parks will…
Coulter Partners successfully completed a search assignment for Altimmune Inc. (Nasdaq: ALT), and is pleased to announce the placement of biopharmaceutical industry executives Teri Lawver and Jerry Durso to its Board of Directors.Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH and other indications.Commenting on the search work with Coulter Partners, Vipin K. Garg, Ph.D., President and Chief…
Howard Group provides local charity with an affordable and well-equipped
new home
Cambridge, 2nd April 2025: Leading regional property investor and developer Howard Group, is delighted to welcome local charity Papworth Trust - a leading disability charity that supports thousands of people, their families and carers every year - to Unity Campus.
The charity has committed to a five-year lease of 3,990 sq ft of ground floor space in the Iconix 1 building and is an excellent addition to the burgeoning and collaborative community of health and science companies at Unity…
AMSBIO has expanded its biofluid collection and processing capabilities, to now offer an unmatched range of customizable human blood biospecimens from both healthy and disease-state donors to support biomedical research.
Leveraging an extensive network of diverse donors, AMSBIO provides high-quality, ethically sourced samples tailored to specific donor demographics, sample volumes, and processing methods.
Using a fully licensed sample collection and processing facility, AMSBIO can ensure the highest standards of traceability and compliance. The expanded portfolio includes…